Several vaccine projects have reported good stimulation of antibody production in trials. The big problem is that we don't yet know what kind of immunity that may provide or how long it might last. But it seems getting people to produce antibodies without making them ill is extremely possible.
From the Moderna Phase I results published recently [1], I'd point out that most vaccine candidates are also performing antibody challenges and T-cell counting, to better characterize the effective immune response generated [2], beyond antibody production.
[2] Via assessment methods in the above: "pseudotyped lentivirus reporter single-round-of-infection neutralization assay (PsVNA) and by live wild-type SARS-CoV-2 plaque-reduction neutralization testing (PRNT)" & "T-cell responses against the spike protein were assessed by an intracellular cytokine–staining assay, performed on specimens collected at days 1, 29, and 43"
